Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04806035
Title Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors TG Therapeutics, Inc
Indications

non-Hodgkin lymphoma

chronic lymphocytic leukemia

Therapies

TG-1801 + Ublituximab

TG-1801

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.